Journal
PHYSICS & IMAGING IN RADIATION ONCOLOGY
Volume 5, Issue -, Pages 9-12Publisher
ELSEVIER
DOI: 10.1016/j.phro.2018.01.001
Keywords
Stereotactic body radiotherapy; Bevacizumab; Colorectal cancer; Liver metastases; CT perfusion
Funding
- Roche Canada
Ask authors/readers for more resources
Stereotactic body radiotherapy (SBRT) and bevacizumab are used in the treatment of colorectal liver metastases. This study prospectively evaluated changes in perfusion of liver metastases in seven patients treated with both bevacizumab and SBRT. Functional imaging using dynamic contrast-enhanced CT perfusion and contrast-enhanced ultrasound were performed at baseline, after bevacizumab, and after SBRT. After bevacizumab, a significant decrease was found in permeability (-28%, p<.05) and blood volume (-47%, p<.05), while SBRT led to a significant reduction in permeability (-22%, p<.05) and blood flow (-37%, p<.05). This study demonstrates that changes in perfusion can be detected after bevacizumab and SBRT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available